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OBJECTIVES: The purpose of this study was to estimate the
preferences of postmenopausal women for disease states associ-
ated with EBC. METHODS: Preferences for relevant health
states and demographic information were obtained from women
aged 55–70 years in the UK and the USA with a history of stage
one or two operable EBC and experience with adjuvant hor-
monal therapy. The 14 health states included in the study, which
were compiled from literature and input from oncologists,
reﬂected the major disease states of breast cancer and the adverse
events reported in the ATAC trial (Cancer 2003; 98:1802–10).
A chained standard gamble (SG) technique was used to compare
health states to perfect and worst health (WH) and then WH
against perfect health and death. WH values were used to rescale
values (0 = death, 1 = perfect health). Pooled and country-
speciﬁc utilities were analysed and compared. RESULTS: A total
of 67 subjects (UK = 23, USA = 44) successfully completed the
SG interviews. There were few differences between country
samples. For the pooled sample, mean age was 67.8 years, 49%
were retired, 61% were living with someone, and 51% had
arthritis. More US than UK women had received radiotherapy
and/or chemotherapy. Raw WH values differed signiﬁcantly
between country samples (UK = 0.844, USA = 0.455; p < 0.001).
Adjusted mean SG scores were 0.432–0.974 for the pooled
sample, 0.710–0.989 for the UK sample, and 0.288–0.965 for
the US sample. Mean current health values for the pooled, UK
and US samples were 0.907, 0.933 and 0.893, respectively.
CONCLUSIONS: The order of adjusted and unadjusted SG
scores within each country was consistent, with the metastatic
breast cancer and disease-free survival with no adverse events
health states being the least and most preferred, respectively.
When comparing utilities across countries, care must be taken in




THE COSTS AND EFFECTS OF CLOPIDOGREL IN 
COMPARISON TO ASA OR PLACEBO FOR SEVERAL 
PATIENT POPULATIONS IN DENMARK
Heeg BMS1, Buskens E1, Hout van BA1
1PharMerit BV,The Netherlands
BACKGROUND: CAPRIE was an international randomized
double blind trial comparing clopidogrel and ASA in patients
with recent MI, stroke or PAD. Post-hoc analyses of the CAPRIE
database identiﬁed three high-risk subgroups in which improved
risk reductions were observed of clopidogrel compared to ASA.
OBJECTIVE: To estimate the long and short term costs and
effects of clopidogrel versus ASA in Denmark in the prevention
of ischemic events (MI, IS, VD) in three high-risk CAPRIE sub-
populations: 1) patients with a history of coronary artery bypass
grafting; 2) patients with a history of ischemic events; 3) patients
with multiple vascular territory involvement. In addition to this,
an analysis for ASA intolerant patients in the general CAPRIE
population was performed. METHODOLOGY: A Markov
model consisting of 24 health states that combined clinical, epi-
demiological and cost data was used to assess the cost and effects
of clopidogrel in comparison to ASA. Only in the ASA intoler-
ant patients, clopidogrel was compared to no treatment.
RESULTS: The comparison of clopidogrel with ASA in the high-
risk CAPRIE sub-groups resulted in cost-effectiveness ratios of
DKK 25,445 (€ 3424) /LYG, DKK 51,198 (€ 6881)/LYG, and
DKK 55,503 (€7460)/LYG for 1) patients with a history of coro-
nary artery bypass grafting; 2) patients with a history of ischemic
events, and 3) patients with multiple vascular territory involve-
ment respectively. The comparison of clopidogrel to no treatment
for the ASA intolerant patients resulted in DKK 3093
(€416)/LYG. Cost-effectiveness ratios of this order are generally
considered acceptable in modern Western societies. Internal and
external validity have been tested and were ascertained. CON-
CLUSION: Clopidogrel may be considered a cost-effective treat-
ment for the prevention of subsequent ischemic events in
high-risk patient populations and in the general CAPRIE-popu-
lation with ASA intolerance in Denmark. Extensive sensitivity
analyses conﬁrmed that these results were stable over the entire
range of assumptions.
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WHAT IS THE ADDED VALUE OF HEALTH RELATED QUALITY
OF LIFE (HRQL) DATA? AN EXAMPLE FROM THE
INTERNATIONAL SUBARACHNOID ANEURYSM TRIAL (ISAT)
Lloyd A1, Scott R2, Carpenter K2
1MEDTAP International, London, UK; 2Oxford University, Oxford, UK
OBJECTIVES: The International Subarachnoid Aneurysm Trial
(ISAT) has revealed signiﬁcantly better clinical outcomes for
patients randomised to endovascular treatment as measured
using the modiﬁed Rankin scale (mRS). ISAT compared the pro-
portion of patients with a mRS grade of three or over (indicates
higher level of impairment and dependency) following endovas-
cular or neurosurgical treatment. The HRQL data were explored
to determine whether there are differences in patients ranked 0–2
on the mRS as well as three or over. METHOD: A sub-sample
of ISAT patients from 8 UK centres completed a thorough assess-
ment of HRQL (SF-36 and Functional Limitations Proﬁle) and
cognitive function at 12 months following treatment. HRQL
data are reported here. Differences were tested using one-way
ANOVA with post-hoc comparisons (LSD) between mRS grades.
RESULTS: Every domain of the SF-36 declines signiﬁcantly with
deteriorating mRS grade. The post-hoc comparisons reveal that
each grade is signiﬁcantly worse than the next lower grade, apart
from grades four and ﬁve. Patients within the 0–2mRS range still
report substantial declines in HRQL (PF is 90.1 at grade zero (n
= 137), to 66.6 at grade 2 (n = 144); VT is 71.6 at grade zero
and 39.9 at grade two; BP is 93.7 at grade zero and 64.0 at grade
2). Sample sizes for grades 3 and over are small, but the data
indicate that little sensitivity to differences in HRQL outcomes
in patients at these higher mRS grades. CONCLUSIONS: The
HRQL data greatly elucidates the differences in health status for
patients at different mRS grades. The HRQL data demonstrate
that simply categorising patients using a single cut-off score on
the mRS is a very crude way of measuring outcomes. Most of
the decline in HRQL scores occurs in the 0–2 range.
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MODELLING SURVIVAL AND COSTS IN SWITZERLAND OF
NESIRITIDE VERSUS INOTROPIC THERAPY FOR ACUTE
DECOMPENSATED HEART FAILURE
Slivinskas J1, Levy AR1, Sendi P2, Brunner-La Rocca HP2,
Gagnon YM1, Briggs A1
1Occam Outcomes Ltd,Vancouver, BC, Canada; 2University Hospital,
Basel, Switzerland
OBJECTIVES: To estimate survival and costs of nesiritide versus
dobutamine or milrinone in patients admitted for acute decom-
pensated heart failure (ADHF) using Swiss University hospital
costs. METHODS: We constructed a decision analytic model of
hospitalisation for ADHF. Subjects started in a hospitalisation
state. Survivors at discharge could be re-hospitalised or die based
on a 6-month Markov process with monthly cycles. Data on sur-
vival and length of stay (LOS) in intensive care or general ward
were tabulated for 9239 patients admitted for heart failure to
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United States hospitals included in the ADHERE patient registry.
All beneﬁts were assumed to accrue in the index hospitalisation
and treatment-speciﬁc lengths of stay were estimated after
adjusting for prognostic indicators. A constant factor was used
to adjust US LOS estimates to reﬂect Swiss patterns. Age-speciﬁc
all-cause mortality at six months was derived from the literature.
Treatment costs are reported in 2003 Swiss francs (CHF) and
include: hospital per diems (from a sample of university hospi-
tals, and including physician costs) and medications for heart
failure. The base-case was estimated for patients aged 75 years
with moderate left ventricular dysfunction (ejection fraction
35–44%). RESULTS: For 1000 subjects admitted with ADHF,
the number of subjects surviving at six month was estimated to
be: 837 for initial treatment with nesiritide, 826 for dobutamine,
and 833 for milrinone. The total cost of treating these cohorts
is estimated at CHF 9.0 million for nesiritide, CHF 10.2 million
for dobutamine, and CHF 11.9 million for milrinone. CON-
CLUSIONS: Based on available data, the base-case shows that
nesiritide is at least as effective as inotrope therapy at reducing
mortality in persons admitted to hospital for ADHF. While the
acquisition cost of nesiritide is higher than that for the inotropes
nesiritide is less costly than inotropic therapy at six months in
Swiss university hospitals.
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PHARMACOECONOMIC CONSEQUENCES OF PRIMARY AND
SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES
IN THE CZECH REPUBLIC
Praznovcova L1, Strnad L2
1Charles University, Faculty of Pharmacy, Hradec Kralove, Czech
Republic; 2University of Management, Hradec Kralove, Czech 
Republic
OBJECTIVES: After 1990, it was recognised that the male pop-
ulation’s life expectancy increased relatively quickly. This elon-
gation was signiﬁcant in decreasing the mortality rate from
diseases of the circulatory system, mainly ischemic heart diseases.
METHODS: Regression cost analysis was used for analysis of
databases such as OECD Health Data, The Ministry of Health
and Statistic institution of the Czech Republic. RESULTS: From
the analysis it is evident that decreasing the concentration of cho-
lesterol in blood plasma of the Czech population (mainly HDL
cholesterol), an exponential increase in the number of people
undergoing cardio surgery and consumption of modern effective
drugs have all had positive effects. Use of antihypertensives in
the years 1994–2003 has increased by more than ten times.
Moreover, use of serum lipid reducing agents has increased sig-
niﬁcantly by more than 15 times since 1995. In 2002 pharma-
ceutical expenditures totaled 48,032 billion Czech crowns (1501
billion €). Use per inhabitant was 4681 Czech crowns (151€).
Cardiovascular drug use was 19.6% of total volume of drugs in
the year 2002. To save one year life in the general population
aged 0–69 years as a result decreasing mortality of ischemic heart
disease, marginal costs for drugs for cardiovascular diseases was
185,000 Czech crowns (5968€). CONCLUSIONS: Drugs for the
treatment of the circulatory system play a signiﬁcant role in drug
policy. The rate of reimbursement drugs from public resources
remains controversial and problems regarding drug policy in the
Czech Republic have not yet been resolved.
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TRENDS IN OUTCOMES AND COSTS FOR U.S. PATIENTS
WITH ADVANCED NON-SMALL LUNG CANCER 1994–2001
Ramsey SD, Howlader N
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
OBJECTIVES: Patients with advanced nonsmall cell lung cancer
have been treated more intensively over the past decade. We
sought to see how changes in treatment intensity inﬂuenced sur-
vival and costs over time. METHODS: Patients ages 65+ diag-
nosed with early stage primary lung cancer were identiﬁed from
the SEER-Medicare database, a national clinical cancer registry
linked to Medicare claims ﬁles. Individuals were included if they
were diagnosed with locally advanced or metastatic (TNM stages
IIIb and IV) NSCLC between January 1, 1994 and December 31,
2001. Kaplan-Meier survival curves were ﬁtted for cohorts diag-
nosed each year from 1994 to 1999. Lifetime medical costs were
calculated for each chemotherapy group using the Kaplan Meier
sample average estimator. To determine whether there was a
trend in costs over time, a regression model was ﬁtted to lifetime
cost estimates for each successive cohort. RESULTS: A total of
14,875 patients met inclusion criteria (approximately 2300 per
year): 7411 (49.8%) stage IIIb and 7464 (50.2%) stage VI at
diagnosis. Proportion of patients receiving procedures in the ﬁrst
three months from diagnosis in 1994 and 1999 were as follows:
no procedure: 38%, 31%; surgery: nine percent (9%), seven
percent (7%), radiation therapy: 47%, 48%; chemotherapy:
27%, 43%. Survival for patients diagnosed in 1994 was 24% at
12 months and 11% at 24 months. Survival for those diagnosed
in 1999 was 27% at 12 and 12% at 24 months (log rank test
for equality, p = 0.57). In constant dollars, lifetime costs per
patient increased from $26,000 to $42,000 over this time period
(OLS regression for time trend: p < 0.002). CONCLUSIONS:
Costs of care for patients with advanced NSCLC diagnosed
between 1994 and 1999 increased 62% with no change in sur-
vival over this time period. Chemotherapy use accounted for the
majority of the increases in treatment intensity and cost.
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COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB + CHOP
VERSUS CHOP IN PATIENTS WITH AGGRESSIVE NON-
HODGKIN LYMPHOMA
Berto P1, Morsanutto A2, Lopatriello S1
1PBE Consulting,Verona,VR, Italy; 2Università di Milano, Milano, Italy
OBJECTIVES: Aim of this study was to evaluate cost-
effectiveness of rituximab + CHOP (R-CHOP) versus CHOP, in
patients affected by aggressive Non-Hodgkin lymphoma, in the
Italian NHS’ perspective. METHODS: The economic analysis is
based on an existing Markov model which was developed in
order to evaluate costs and effects for two hypotetical cohorts of
patients of age respectively higher and lower than 60 years, over
a time frame of 15 years after administration of chemotherapy.
The model is based on 5 health states (start therapy, complete
response, no response, progression, death) and combines efﬁcacy
data from published clinical trials (GELA-98-5) with utilities
from the literature and cost of therapies and medical follow-up
after chemotherapy, based on Italian treatment patterns. Costs
and effects were discounted respectively at 6% and 1,5%. Exten-
sive 1-way and Monte Carlo sensitivity analyses were conducted
in order to test the robustness of results. RESULTS: For the 2
cohorts (60+; 60-), incremental discounted Life Years Gained
with R-CHOP versus CHOP were respectively 1.08 and 1.02
years; incremental QALYs were 1.15 and 1.04; the incremental
cost/patient was 14.838€ and 13.938€; the incremental cost/LYG
was therefore 13.732€ and 13.717€ and the incremental
cost/QALY was 12.879€ and 13.362€, respectively for 60+ and
60- patients. CONCLUSIONS: The clinical advantage of R-
CHOP is supported by incremental cost/LYG and cost/QALY
ratios which fall well below all the thresholds commonly indi-
cated for these values both in the international and italian liter-
ature. R-CHOP is a substantial improvement in the treatment of
